The FDA approved Foundayo (orforglipron), a GLP-1-type peptide drug, on April 1, 2026, to help adults with obesity or overweight lose weight and keep it off when used with diet and exercise. The agency also cleared Awiqli (insulin icodec-abae), a long-acting insulin peptide, for blood sugar control in type 2 diabetes on March 26, 2026.

• •FDA approved Foundayo (orforglipron) on 4/1/2026 for obesity/overweight with comorbidity
• •Indication requires combination with reduced-calorie diet and increased physical activity
• •FDA also cleared Awiqli (insulin icodec-abae) on 3/26/2026 for type 2 diabetes glycemic control